Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), and Fibromyalgia.

Exciting News! Researchers Identify Characteristic Chemical Signature for Chronic Fatigue Syndrome

Dr. Ronald Davis, Director of the Open Medicine Foundation Scientific Advisory Board, reports that “this is the best study on ME / CFS that has ever been done and it will transform research, diagnosis and treatment.” Dr. Davis’s review of the Naviaux RK, et al.’s publication “Metabolic features of Chronic Fatigue Syndrome” in the Proceedings of the National Academy of Sciences brings hope and excitement to the ME / CFS community.

Dr. Davis said, “This is the most important and groundbreaking study of ME / CFS to date.”  The study reveals a metabolic ‘signature’ that could potentially distinguish ME / CFS patients from healthy individuals. Read Dr. Ron Davis’ complete remarks regarding the metabolic signature of Chronic Fatigue Syndrome.

Recognizing the important implications of this study, Open Medicine Foundation (OMF) has already launched a validation study with Dr. Robert Naviaux at University California at San Diego. This Expanded Metabolomics study is hoping to validate the original findings with a larger cohort of ME / CFS patients and healthy controls and to evaluate the contribution of genetics to the variation in observed metabolic signatures in this disease. Dr. Naviaux, also a member of the OMF Scientific Advisory Board, is partnering with Dr. Davis in this expanded validation study.

In the recent National Institute for Health Request for Information, metabolomics was the most requested area of focus.  OMF is very excited to be a partner funding the validation study. We anticipate that additional research opportunities will present as the validation study advances. We invite the community to help OMF fund these research opportunities to fast-track answers. Please donate to fast-track ME / CFS research.

Stay Informed

Be the first to hear our research news.

Subscribe Now.

No thanks